MSN Group launches urinary incontinence drug Fesobig
The drug is an affordable treatment for overactive bladder
Hyderabad-based MSN Labs has launched Fesobig, the world’s first bioequivalent generic version of Fesoterodine Fumarate. Fesobigis recommended as the safest, novel first-line pharmacotherapy option by various international treatment guidelines for the treatment of overactive bladder (OAB) and Urinary Incontinence (UI).
“The launch of Fesobig (Fesoterodine) tablets is in line with our ongoing commitment to research in bringing affordable medications across critical therapies for alleviating the suffering of the Indian patients,” Dr MSN Reddy, CMD, MSN Group commented.
Speaking on occasion, Bharat Reddy, Executive Director, MSN Group, said, “Besides helping recover from overactive bladder (OAB), we are certain that Fesobig will endow patients with a much more confident way of life by eliminating the social and psychological discomfort associated with the condition. We have ensured that the drug is priced affordably so that it can benefit a vast majority of patients.”
The guest speaker Dr K Lalitha, consultant urologist spoke on the prevalence of OAB in India. According to the studies,1 in 3 women above the age of 50 suffers from urinary incontinence impacting their quality of life.
Dr Anuradha Koduri, HOD – Gynecology, KIMS Hospital, spoke on the social stigma associated with the condition and stated that a majority of patients shy away from treatment due to the lack of awareness and accept it as a part of the ageing process. This, in the long run, leads to various medical complications.
Dr A V Ravikumar, consultant urologist further elucidated the various medical avenues including behavioural therapy, drugs and surgical options available in treating OAB.